Physician profile
Marianne E Dawn
NPI 1033252390
$15,419.60
in general payments reported to CMS, 2019-2025
40 companies · $3,836 in 2025
The $3,836 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,936 · 2020: $881 · 2021: $1,057 · 2022: $2,027 · 2023: $2,715 · 2024: $2,967 · 2025: $3,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,323 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,323.43 |
| Education | $195.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,216.17 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,802.40 | 2019-2025 | |
| Pfizer INC. | $1,111.83 | 2019-2025 | |
| Dermavant Sciences, INC. | $1,069.25 | 2022-2024 | Vtama |
| Genzyme Corporation | $1,041.14 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $984.52 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $981.91 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $772.53 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $755.24 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $740.77 | 2020-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $737.67 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Sun Pharmaceutical Industries INC. | $587.15 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Leo Pharma INC. | $477.50 | 2019-2025 | Adbry, Anzupgo |
| Organon LLC | $394.25 | 2024-2025 | Vtama, Nexplanon |
| Almirall LLC | $310.12 | 2019-2025 | Klisyri |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marianne Dawn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.